Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
---|---|---|---|---|---|---|
Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
Historisch | Analysen |
30.06.2025 07:00:05
|
BIOVERSYS ANNOUNCES RESULTS FROM its ANNUAL GENERAL MEETING OF SHAREHOLDERS
BioVersys AG / Key word(s): AGMEGM Ad hoc announcement pursuant to Art. 53 LR
BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant ("MDR") bacteria, today announced the results of the Company’s Annual General Meeting (AGM) of Shareholders held on June 27, 2025.
A total of 55.4% of the Company’s share capital was represented at the meeting.
All items on the agenda received the required majority of votes in favor, including:
Dr. Seng Chin Mah, Chairman of the Board of the Directors commented: “I would like to thank our shareholders for their continued strong support of our strategy as we embark on the final clinical development phase for BV100 with the initiation of Phase 3 later in the year. We will also continue to progress our second clinical asset, alpibectir, as well as our preclinical projects. We remain committed to bringing our novel therapies to patients in dire need and to returning stakeholder value. The Board of Directors and Management would also like to thank Dr. Henni Ropponen for her invaluable contributions during her board tenure and we welcome Dr. Ulrik Schulze to the Board of Directors.”
The minutes and the relevant documents relating to the shareholders’ meeting, including the Annual Report, will be available on the Company’s website under the following links: Annual Report: https://ir.bioversys.com/investor-relations/financials/financial-reports AGM: https://ir.bioversys.com/investor-relations/governance-csr/annual-general-meeting
BioVersys contact End of Inside Information |
2162098 30-Jun-2025 CET/CEST
Nachrichten zu BioVersys
17.07.25 |
Freundlicher Handel in Zürich: So performt der SPI aktuell (finanzen.ch) | |
14.07.25 |
SIX-Handel SPI beendet den Handel kaum bewegt (finanzen.ch) | |
14.07.25 |
Minuszeichen in Zürich: SPI sackt nachmittags ab (finanzen.ch) | |
14.07.25 |
Angespannte Stimmung in Zürich: SPI notiert mittags im Minus (finanzen.ch) | |
11.07.25 |
Schwacher Wochentag in Zürich: SPI leichter (finanzen.ch) | |
04.07.25 |
Schwacher Handel: SPI beginnt Freitagshandel mit Verlusten (finanzen.ch) | |
02.07.25 |
BioVersys-Aktie gewinnt: BioVersys fliessen dank Forschungsabkommen 5 Millionen Franken zu (AWP) | |
02.07.25 |
Zuversicht in Zürich: SPI präsentiert sich fester (finanzen.ch) |
3 Knaller-Aktien 📈im BX Musterportfolio: Quanta Services, Commerzbank & Broadcom mit François Bloch
Im BX Morningcall werden folgende Aktien analysiert und erklärt:
✅ Quanta Services
✅ Commerzbank
✅ Broadcom
Pünktlich zum Börsenstart diskutieren Investment-Stratege François Bloch und Börsen-Experte David Kunz oder Olivia Hähnel über ausgewählte Top-Aktienwerte aus dem BX Musterportfolio.
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
Zoll-Einigung USA-EU: SMI und DAX fester -- Asiens Börsen letztlich uneinheitlichAm heimischen sowie deutschen Aktienmarkt herrscht am Montag gute Stimmung. Die Börsen in Fernost fanden zum Wochenstart keine gemeinsame Richtung.
finanzen.net News
Datum | Titel |
---|---|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |